Fruquintinib combined with FOLFIRI/mFOLFOX6 as second-line treatment in patients with RAS-mutant metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study. This is an ASCO Meeting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results